AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ACH

Accendra Health Inc (ACH) (Q3 2026) Earnings Call Highlights: Revenue Slips 1% as Guidance

Accendra Health Inc (ACH) reported a 1% revenue decline in Q3 2026, its first annual drop, with adjusted EBITDA at $47.8M. Full-year adjusted EBITDA may be 30% below prior guidance. The company lost market share in sleep and respiratory, and faces operational challenges. Management expects to resolve commercial payer audit issues by Q4 2026 and outlined a turnaround plan for 2027. Net debt is $1.73B, with strong liquidity.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 9:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Accendra Health Inc (ACH) (Q3 2026) Earnings Call Highlights: Revenue Slips 1% as Guidance — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ACHBearishMed
01

Why it matters

The earnings miss and guidance downgrade are likely to trigger short‑term selling pressure, though the company retains liquidity and a modest asset sale pipeline.

02

Market read

First report of earnings and guidance downgrade for Accendra; material for traders focused on small‑cap healthcare stocks.

03

What to watch

The pending non‑core asset sale (~$14 M) and extended receivables securitization facility provide liquidity cushion not fully reflected in the price.

Relevance 7/10Novelty 7/10Timing: post‑market earnings call

Background

Accendra Health Inc (ACH) reported its Q3 2026 results, highlighting a 1% revenue decline and a significant EBITDA guidance cut.

Company-level read

Ticker impact

$ACHBearishHigh confidence
Context

Q3 2026 earnings call disclosed revenue down 1% YoY and full-year adjusted EBITDA guidance cut up to 30% below prior midpoint.

Expected impact

likely downside as market prices in weaker revenue and EBITDA outlook

Evidence & confidence

First disclosure of lower guidance and revenue decline; investors typically react negatively to earnings shortfalls.

Market effects

Sector

Healthcare services sector may see modest pressure as Accendra signals weaker demand in sleep and respiratory segments.

Regional

U.S. small‑cap healthcare stocks could face slight pullback.

Global

Limited; impact confined to Accendra and close peers.

Counterpoint

What could challenge this read

If the company successfully executes its turnaround plan in 2027, the stock could be oversold after this dip.

Key entities

  • Company
    Accendra Health Inc

    U.S. healthcare services firm reporting Q3 2026 earnings.

  • Executive
    Kenny Gardner‑Smith

    CEO discussing turnaround plan.

  • Executive
    Jonathan Leon

    CFO providing financial details and guidance.

Read at source← All news

Also covered by

2 outlets

Related articles

$ACHMed

Accendra (ACH) Q3 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q3 2026 revenue of $602M, down 1% YoY, excluding impacts from a large commercial payer loss and asset sale. Adjusted EBITDA was $47.8M. CEO Kenny Gardner-Smith outlined a value creation plan to address performance issues, focusing on reversing revenue declines and improving collections. CFO Jonathan Leon highlighted liquidity strength and debt reduction.

finance.yahoo.com
$ACHMedAI 8/10

Accendra Health Reports Third Quarter 2026 Financial Results

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Accendra Health Reports Third Quarter 2026 Financial Results ​ RICHMOND, VA – November 5, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herei

SEC EDGAR 8-K
$ACHHighAI 8/10

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.

aol.com
$ACHMedAI 8/10

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.

fool.com
$ACHMedAI 8/10

Accendra Health Reports Lower Q2 Revenue, Sets 2026 Guidance; Adopts Tax Asset Plan; Stock Down

Accendra Health (ACH) reported Q2 2026 revenue of $613.2 million, down from $681.9 million a year earlier, with GAAP net loss of $89.1 million ($1.16/share). Non-GAAP adjusted net loss was $14.3 million. Adjusted EBITDA fell to $60.1 million and free cash flow was -$25.1 million. The company guided FY2026 revenue $2.45-$2.55 billion and adjusted EBITDA $300-$320 million, and adopted a tax asset preservation plan.

rttnews.com